Professional Marketing briefs: May 2013

Share this article:
AstraZeneca, J&J enter cancer collaborations
AstraZeneca, J&J enter cancer collaborations

Bristol Myers-Squibb will shut now-subsidiary Amylin's San Diego site by 2014. The closing will affect 420 employees who work in R&D, commercial, manufacturing, corporate and administrative positions. BMS also is merging its Ohio workforce with that of Amylin's, a change that will have an impact on the staff who fill Amylin's 400 in-field sales and medical roles. BMS bought Amylin in August 2012, paying $5.3 billion and assuming $1.7 billion in debt.

AstraZeneca announced 3,900 layoffs in March, which will be spread out over the next three years. Sales and adminis­trative positions are among the jobs to be cut. A spokesman told MM&M the bulk of the losses will be in Europe and that some layoffs were previously known about internally.

Accenture's latest numbers indicate that pitching on a doctor's turf will increasingly mean working with fewer clinician owners, reported Amednews. Accenture found “36% of practicing physicians will hold a practice ownership stake by the end of 2013, a decline from 57% in 2000.” Amednews said to also expect high turnover at these businesses because no ownership stake to sell, means an easier exit.
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Private View: Discussing Women's Health

Private View: Discussing Women's Health

Dan Chichester, chief creative officer, LLNS